ERBB2 and endometrial serous adenocarcinoma: Trastuzumab, a humanized monoclonal antibody targeting Her2/Neu, has been studied in advanced/recurrent uterine-serous carcinomas in combination with carboplatin and paclitaxel in a phase II study that showed clinical benefit [35].